News Releases

Keyword Search

Oct-06-2020
Oncternal Therapeutics Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TK216 for Treatment of Ewing Sarcoma
Sep-21-2020
Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at ESMO Virtual Congress 2020
Sep-10-2020
Oncternal Therapeutics to Participate in September Investor Conferences
Aug-27-2020
Oncternal Therapeutics Increases Previously Announced Bought Deal to $4.5 Million
Aug-27-2020
Oncternal Therapeutics Announces $3.5 Million Bought Deal Offering
Aug-06-2020
Oncternal Provides Business Update and Announces Second Quarter 2020 Financial Results
Jul-30-2020
Oncternal Therapeutics to Report Second Quarter 2020 Financial Results and Provide Business Update
Jul-27-2020
Oncternal Therapeutics to Host Call on Cirmtuzumab and the Current Treatment Landscape for Mantle Cell Lymphoma
Jul-20-2020
Oncternal Therapeutics Announces $6.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Jun-30-2020
Oncternal Therapeutics Announces Orphan Drug Designations of Cirmtuzumab ROR1 Antibody for Treatment of Mantle Cell Lymphoma and for Treatment of Chronic Lymphocytic Leukemia